Trials / Recruiting
RecruitingNCT07101094
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | xanomeline and trospium chloride (X/T) therapy | According to the product label |
Timeline
- Start date
- 2025-09-22
- Primary completion
- 2029-01-31
- Completion
- 2029-05-14
- First posted
- 2025-08-03
- Last updated
- 2026-04-13
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07101094. Inclusion in this directory is not an endorsement.